Measuring Brain Amyloid Plaque Load in Older Adults Using BAY 94-9172
Status:
Active, not recruiting
Trial end date:
2029-01-01
Target enrollment:
Participant gender:
Summary
The overall goal of this project is to establish and validate biomarkers associated with the
risk and progression of late onset Alzheimer's disease, mild cognitive impairment and
cognitive decline. The investigators will use baseline and longitudinal measurements of
plasma amyloid beta-40 and amyloid beta-42 to investigate the risk of developing mild
cognitive impairment and late onset Alzheimer's disease, as well as the rates of cognitive
decline and Alzheimer's disease progression. Participants will be selected on the basis of
change in plasma amyloid beta levels over prior assessment intervals. The purpose of the
study is to examine whether brain amyloid plaque load, which will be measured with positron
emission tomography and x-ray computed tomography brain imaging using Florbetaben from Bayer,
varies as a function of change in plasma levels of amyloid beta. The driving hypothesis of
the study is that high plasma levels of amyloid beta are an antecedent indicator of increased
risk of cognitive decline, mild cognitive impairment, and incident late onset Alzheimer's
disease, and that declining plasma levels of amyloid beta are associated with the onset of
cognitive decline. Further, high plasma levels of amyloid beta are related to increased
levels of amyloid beta in the brain as measured by positron emission tomography positivity,
and the specific pattern of positron emission tomography positivity and a decline in plasma
amyloid beta over time are associated with the onset of cognitive decline associated with
late onset Alzheimer's disease.